Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting has been inconsisten...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Hockaday, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Gregory, Walter M, Morgan, Gareth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318225/
https://www.ncbi.nlm.nih.gov/pubmed/30559051
http://dx.doi.org/10.1016/S1470-2045(18)30687-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318225/
https://www.ncbi.nlm.nih.gov/pubmed/30559051
http://dx.doi.org/10.1016/S1470-2045(18)30687-9

Ejemplares similares